Slower gait speed, but not handgrip strength or muscle mass, is associated with an increased risk for cardiovascular outcomes ...

Home-based cardiac rehabilitation is noninferior to center-based programs for improving fitness and quality of life for patients with heart failure.

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Cumberland Pharmaceuticals has reported positive outcomes from a trial of ifetroban as a potential treatment for Duchenne ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

USA: The recent RELIEVE-HF trial has revealed the efficacy of transcatheter interatrial shunt implantation as a treatment for ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...